A prospective phase II study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinoma-Reference-Cited by-同舟云学术

A prospective phase II study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinoma

Published:2018-04 Issue:4 Volume:29 Page:979-984
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Fushimi C.^ORCID,Tada Y.,Takahashi H.,Nagao T.,Ojiri H.,Masubuchi T.,Matsuki T.,Miura K.,Kawakita D.,Hirai H.,Hoshino E.,Kamata S.,Saotome T.

Funder

Japan Society for the Promotion of Science

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/29/4/979/25082495/mdx771.pdf

Reference28 articles.

1. The burden of rare cancer in Japan: application of the RARECARE definition;Tamaki;Cancer Epidemiol,2014

2. RARECARE. RARECARE Cancer List. Available at: http://www.rarecare.eu/rarecancers/rarecancers.asp (6 July 2017, date last accessed).

3. Incidence of carcinoma of the major salivary glands according to the WHO classification, 1992 to 2006: a population-based study in the United States;Boukheris;Cancer Epidemiol Biomarkers Prev,2009

4. Diagnosis and management of malignant salivary gland tumors of the parotid gland;Lewis;Otolaryngol Clin North Am,2016

5. Clinical outcomes and prognostic factors for salivary duct carcinoma: a multi-institutional analysis of 141 patients;Otsuka;Ann Surg Oncol,2016

Cited by 159 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Different characteristics of the tumor immune microenvironment among subtypes of salivary gland cancer;Asia-Pacific Journal of Clinical Oncology;2024-09-04

2. PD-L1 expression as a predictive biomarker in patients with recurrent or metastatic salivary gland carcinoma treated with pembrolizumab;Scientific Reports;2024-08-27

3. Recurrence after primary salivary gland carcinoma: Frequency, survival, and risk factors;Head & Neck;2024-07-27

4. High-grade salivary carcinomas: A current insight on diagnostic pathology and the key to clinical decision making;Seminars in Diagnostic Pathology;2024-07

5. Apalutamide and Goserelin for Androgen Receptor–Positive Salivary Gland Carcinoma: A Phase II Nonrandomized Clinical Trial, YATAGARASU;Clinical Cancer Research;2024-06-28